Luke Kromenhoek throws 3 TD passes as Florida St. ends six-game skid vs. Charleston SouthernRyan Specialty Holdings, Inc. (NYSE:RYAN) Shares Sold by Swiss National Bankwolfy casino bonus ohne einzahlung 。

Taurus Daily Horoscope Today, November 27 2024 advices to avoid investing in stocks

After a tough loss on the road their last time out, Air Force looks much better today on their home court. They have jumped out to a quick 31-24 lead against Mercyhurst. Air Force entered the match with three straight defeats and they're well on their way to making it four. Can they turn things around, or will Mercyhurst hand them another loss? Only time will tell. Mercyhurst Lakers @ Air Force Falcons Current Records: Mercyhurst 4-2, Air Force 1-4 When: Sunday, November 24, 2024 at 4 p.m. ET Where: Clune Arena -- Colorado Springs, Colorado Follow: CBS Sports App Online streaming: fuboTV (Try for free. Regional restrictions may apply.) Ticket Cost: $12.00 The Mercyhurst Lakers will face off against the Air Force Falcons at 4:00 p.m. ET on Sunday at Clune Arena. The Lakers will be strutting in after a victory while the Falcons will be stumbling in from a loss. Mercyhurst is headed in fresh off scoring the most points they have all season. They steamrolled past Mount Aloysius 98-45 on Tuesday. The matchup was pretty much decided by the half, when the score had already reached 54-23. Mercyhurst smashed the offensive glass and finished the game with 20 offensive rebounds. They easily outclassed their opponents in that department as Mount Aloysius only pulled down three. Meanwhile, Air Force's recent rough patch got a bit rougher on Thursday after their third straight defeat. They took a 78-69 hit to the loss column at the hands of California. Air Force's loss came about despite a quality game from Ethan Taylor, who went 9 for 13 en route to 23 points. Mercyhurst's win was their third straight at home, which pushed their record up to 4-2. As for Air Force, their defeat dropped their record down to 1-4. Mercyhurst is hoping to beat the odds on Sunday, as the experts think they're headed for a loss. Air Force is a big 9.5-point favorite against Mercyhurst, according to the latest college basketball odds . The oddsmakers had a good feel for the line for this one, as the game opened with the Falcons as a 10-point favorite. The over/under is 129 points. See college basketball picks for every single game, including this one, from SportsLine's advanced computer model. Get picks now .These travelers are fed up, looking for 'simpler times.' Here's where they're going.

Media Release COPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE ® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) who received epcoritamab monotherapy In the study, 75 percent of evaluable responders achieved undetectable minimal residual disease (MRD), indicating no detectable disease following treatment with epcoritamab The data were selected as part of the 2024 American Society of Hematology’s (ASH’s) Annual Meeting Press Program in the Diagnosing and Treating Blood Cancers and “Almost Cancers” briefing Genmab A/S (Nasdaq: GMAB ) today announced results from the Phase 1b/2 EPCORE ® CLL-1 clinical trial evaluating epcoritamab (Abstract #883), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 61 percent and a complete response (CR) rate of 39 percent in difficult-to-treat adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with epcoritamab monotherapy. These results, from the monotherapy expansion (EXP) cohort (n=23) of the trial, along with the first safety data from the optimization (OPT) cohort, were presented at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH), during the ASH Annual Meeting Press Program. The data will be presented during an oral session on December 9, 2024. In the EXP cohort, the median time to response was two (2.0) months and the median time to CR was 5.6 months. Among all patients in the cohort, median progression-free survival (PFS) was 12.8 months and median overall survival (OS) was not reached (median follow-up was 22.8 months). An estimated 65 percent of patients were alive at 15 months. Among 12 responders evaluable for minimal residual disease (MRD) by next-generation sequencing in peripheral blood, nine patients (75 percent) had undetectable MRD. The most frequent non-hematologic treatment-emergent adverse events (TEAEs) in the EXP cohort were cytokine release syndrome (CRS; 96 percent), diarrhea (48 percent), peripheral edema (48 percent), fatigue (43 percent), and injection-site reaction (43 percent). Cytopenias were common (anemia, 65 percent; thrombocytopenia, 65 percent; neutropenia, 48 percent); however, most patients had baseline anemia and thrombocytopenia, suggesting that these events were largely disease-related. Three cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported (one Grade 1; two Grade 2), and there was one clinical tumor lysis syndrome (CTLS) case (Grade 2). These cases did not lead to treatment discontinuation. Four fatal TEAEs occurred - two cases of pneumonia, one case of sepsis and one case of squamous cell carcinoma of the skin. The EXP cohort followed a 2-step step-up dose regimen, and CRS was manageable and primarily low grade (9 percent Grade 1, 70 percent Grade 2, 17 percent Grade 3). In the first data from the separate OPT cohort, which followed a 3-step step-up dose regimen, CRS severity was substantially reduced with only low-grade events (71 percent Grade 1, 12 percent Grade 2). In both cohorts, CRS events primarily occurred following the first full dose, and none led to treatment discontinuation. No ICANS or CTLS cases were reported in the OPT cohort. “These EPCORE CLL-1 data are encouraging, especially as the majority of patients were heavily pre-treated with at least four lines of therapy,” said Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus, Professor and Director of Early Clinical Therapeutics and Associate Director of the Toni Stephenson Lymphoma Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope. “Despite progress in treating chronic lymphocytic leukemia, there remains a tremendous need for additional therapeutic options for high-risk patients whose disease has progressed following standard chemoimmunotherapy and targeted therapies.” Additional data from the EXP cohort showed high response rates in patients with high-risk factors treated with epcoritamab, including TP53 aberrations, IGHV-unmutated disease and double-exposed disease – prognostic markers that are associated with disease progression and decreased survival. i , ii , iii In patients with TP53 aberrations (n=15), the ORR was 67 percent with a CR of 33 percent. Among patients with IGHV-unmutated disease (n=16), the ORR was 63 percent, and the CR was 44 percent. In double-refractory patients, the ORR was 53 percent, and the CR was 37 percent. All patients in the trial had prior chemoimmunotherapy, and most patients had previously received targeted therapies such as BTK and BCL2 inhibitors (double-exposed) and had high-risk disease characteristics. “Chronic lymphocytic leukemia is incurable, and patients often need a variety of treatments throughout their lifetime, especially if their disease has high-risk prognostic factors, has relapsed or has become refractory to the current standard-of-care, including targeted therapies,” said Dr. Judith Klimovsky, Executive Vice President & Chief Development Officer, Genmab. “These early data show the potential therapeutic applicability of epcoritamab in relapsed or refractory chronic lymphocytic leukemia, and further reinforce the potential of epcoritamab as a core therapy for the treatment of B-cell malignancies.” Use of epcoritamab in CLL is not approved in the U.S. or in the EU or in any other territory. The safety and efficacy of epcoritamab for use in CLL have not been established. About Chronic Lymphocytic Leukemia (CLL) Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia, affecting over 200,000 people in the United States alone. iv Chronic lymphocytic leukemia can be classified as either slow growing (indolent) or fast growing (aggressive). v CLL is incurable, and many patients will likely relapse and progress on frontline therapies. vi Most patients will experience consecutive episodes of disease progression and will require several lines of treatment in their lifetime. vii , viii About the EPCORE ® CLL-1 Trial EPCORE ® CLL-1 is a Phase 1b/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of epcoritamab as a monotherapy and in combination with standard of care agents in patients with difficult-to-treat relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), R/R small lymphocytic lymphoma (SLL) and Richter's Syndrome (RS). The trial consists of two parts: a dose-escalation phase (Phase 1b) and an expansion phase (Phase 2). Patients with RS are only included in the expansion phase. The primary objective of Phase 1b is to determine the recommended Phase 2 dose and the maximum tolerated dose as well as establish the safety profile of epcoritamab monotherapy and epcoritamab plus venetoclax in participants with R/R CLL. The purpose of Phase 2 is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab monotherapy and epcoritamab plus venetoclax for patients with R/R CLL and SLL. Additionally, epcoritamab monotherapy and combination therapy will be evaluated in patients with RS to assess their efficacy, safety and tolerability profiles. More information on this trial can be found at https://www.clinicaltrials.gov/ (NCT: 04623541). About Epcoritamab Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody ® technology and administered subcutaneously. Genmab's DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T-cell-mediated killing of CD20+ cells. ix Epcoritamab (approved under the brand name EPKINLY ® in the U.S. and Japan, and TEPKINLY ® in the EU) has received regulatory approval in certain lymphoma indications in several territories. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization. Both companies will pursue additional international regulatory approvals for the investigational R/R FL indication and additional approvals for the R/R DLBCL indication. Genmab and AbbVie continue to evaluate the use of epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes five ongoing Phase 3, open-label, randomized trials including a trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL compared to investigator’s choice chemotherapy ( NCT04628494 ), a trial evaluating epcoritamab in combination with R-CHOP in adult patients with newly diagnosed DLBCL ( NCT05578976 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) in patients with R/R FL ( NCT05409066 ), a trial evaluating epcoritamab in combination with rituximab and lenalidomide (R 2 ) compared to chemoimmunotherapy in patients with previously untreated FL ( NCT06191744 ), and a trial evaluating epcoritamab in combination with lenalidomide compared to chemotherapy infusion in patients with R/R DLBCL ( NCT06508658 ). The safety and efficacy of epcoritamab has not been established for these investigational uses. Please visit www.clinicaltrials.gov for more information. About Genmab Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO ® ) antibody medicines. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X . Contact: David Freundel, Senior Director, Global R&D & Portfolio Communications T: +1 609 430 2481; E: dafr@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo ® ; HuMax ® ; DuoBody ® ; HexaBody ® ; DuoHexaBody ® , HexElect ® and KYSOTM. EPCORE ® , EPKINLY ® , TEPKINLY ® and their designs are trademarks of AbbVie Biotechnology Ltd. i Campo, et al. TP53 Aberrations in Chronic Lymphocytic Leukemia: An Overview of the Clinical Implications of Improved Diagnostics. Haematologica . 2018 Nov 15;103(12):1956–1968. https://haematologica.org/article/view/8691 .. ii Galieni, et al. Unmutated IGHV at Diagnosis in Patients With Early Stage CLL Independently Predicts for Shorter Follow-Up Time to First Treatment (TTFT). Leukemia Research. 2024. https://doi.org/10.1016/j.leukres.2024.107541 . iii Zuber, et al. Efficacy and Effectiveness Outcomes of Treatments for Double-Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review. Cancer Medicine . 2024. https://doi.org/10.1002/cam4.70258 iv Fedele, et al. Chronic Lymphocytic Leukemia: Time to Care for the Survivors. Journal of Clinical Oncology . 2024. https://ascopubs.org/doi/10.1200/JCO.23.02738 . v Penn Medicine. Chronic Lymphocytic Leukemia (CLL). Accessed November 2024. https://www.pennmedicine.org/cancer/types-of-cancer/leukemia/types-of-leukemia/chronic-lymphocytic-leukemia . vi Odetola, et al. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Curr Hematol Malig Rep . 2023 Jun 6:1–14. doi: 10.1007/s11899-023-00700-z vii Moreno, Carol. Standard Treatment Approaches for Relapsed/Refractory Chronic Lymphocytic Leukemia After Frontline Chemoimmunotherapy. Hematology Am Soc Hematol Educ Program . 2020 Dec 4;2020(1):33-40. doi: 10.1182/hematology.2020000086. viii Leukemia & Lymphoma Society. Relapsed and Refractory CLL. Accessed November 2024. https://www.lls.org/leukemia/chronic-lymphocytic-leukemia/treatment/relapsed-and-refractory . ix Engelberts PJ, et al. DuoBody-CD3xCD20 Induces Potent T-Cell-Mediated Killing of Malignant B Cells in Preclinical Models and Provides Opportunities for Subcutaneous Dosing. EBioMedicine . 2020;52:102625. doi: 10.1016/j.ebiom.2019.102625. Media Release no. i19 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122 Genmab A/S Carl Jacobsens Vej 30 2500 Valby Denmark Attachment 081224_MRi19_Epcor CLL ASH Data GLOBALHundreds pack Union Station for 9th annual tree lighting ceremony

NoneKura Oncology ( NASDAQ:KURA – Get Free Report ) had its price target boosted by equities researchers at HC Wainwright from $32.00 to $37.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 242.59% from the company’s previous close. Other analysts have also issued reports about the stock. UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday. Stifel Nicolaus cut Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the stock from $26.00 to $19.00 in a research report on Monday, October 14th. Finally, StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.38. Get Our Latest Stock Analysis on Kura Oncology Kura Oncology Stock Performance Institutional Investors Weigh In On Kura Oncology Several institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Kura Oncology during the 1st quarter valued at $110,000. ProShare Advisors LLC raised its position in shares of Kura Oncology by 9.7% in the first quarter. ProShare Advisors LLC now owns 18,014 shares of the company’s stock valued at $384,000 after purchasing an additional 1,588 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after buying an additional 28,212 shares during the period. Avoro Capital Advisors LLC grew its stake in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after buying an additional 870,000 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Kura Oncology by 17.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 20,148 shares of the company’s stock worth $430,000 after acquiring an additional 2,940 shares during the period. About Kura Oncology ( Get Free Report ) Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. See Also Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter .People with could soon be able to watch TV without worry. Scientists in the UK have created glasses that can block out specific wavelengths of light known to cause seizures. It’s estimated that about have photosensitive epilepsy, and as the name suggests their seizures are triggered by light. Flashing and alternating patterns, such as those in clubs, emergency vehicles, television, movies and video games, can all be triggers if they have just the right mix of brightness, frequency and wavelength. Now, scientists at the Universities of Glasgow and Birmingham have developed a pair of glasses that could help reduce the risk. The lenses are designed to block out almost all light with wavelengths between 660 and 720 nanometers – a region of red light that was implicated in the in 1997, which triggered seizures in hundreds of viewers. These lenses contain liquid crystals that change their optical properties in response to heat. In this case, the frames of the glasses has a small circuit that heats the lenses up to 36.5 °C (97.7 °F), which causes them to reflect those particular wavelengths of red light. The idea there is that people could wear them out and about with normal vision most of the time, but could switch them on when they want to watch TV or play video games without worrying about having a reaction. Previous studies have used colored lenses to achieve a similar effect, but these only filtered about 50% of the targeted red light. On top of that, they don’t switch on and off, so affect the color vision of the wearer in all situations rather than just those with high-risk of seizures. In its current form, the glasses can only work in environments of up to 26 °C (78.8 °F), so this is something that the team plans to continue working on. In addition, they want to reduce the time it takes to activate them. The research was published in the journal . Source:Sunday's inaugural 12-team College Football Playoff bracket reveal officially set the stage for the most anticipated postseason the sport has ever seen. Eight more spots in the playoff field have created two extra rounds to determine a national champion, which could come from the Big Ten, the Southeastern Conference or even the Mountain West! Now that the initial matchups are set, it's time to examine the FanDuel odds for the first-round games and, of course, the latest national championship odds. CFP Bracket: Odds for First-Round Games Oregon's win over Penn State in the Big Ten championship locked the Ducks into the No. 1 seed, while Georgia's overtime triumph over Texas for the SEC crown moved the Bulldogs up to No. 2. Boise State slotted in at No. 9 in the final CFP rankings but is the No. 3 seed thanks to its win over UNLV in the Mountain West championship. With SMU losing to Clemson in the Atlantic Coast Conference title game, No. 12-ranked Arizona State is the four seed after it throttled Iowa State to win the Big 12. The top four teams get a bye, with the 5-12 seeds meeting in the first round. 12-seed Clemson (+330) vs. 5-seed Texas (-11.5) Texas was favored to win the SEC and lock down a top-four seed, but Clemson was not expected to beat SMU for the ACC title. The Longhorns will therefore hunt redemption, while Dabo Swinney's team is essentially playing with house money. The winner will face Arizona State in the Peach Bowl. 9-seed Tennessee (+215) vs. 8-seed Ohio State (-7.5) The third-highest-ranked team from the SEC (No. 7 Tennessee) will face off with the third-highest-ranked squad from the Big Ten (No. 6 Ohio State). This game brings the Buckeyes a chance at redemption for their embarrassing loss to Michigan to end the regular season. The winner will travel to the Rose Bowl to play Oregon. 11-seed SMU (+240) vs. 6-seed Penn State (-7.5) Concerns over strength of schedule dog both teams. Both have 11-2 records and were runners-up in their respective conferences. Penn State's only win over a ranked opponent was against then-No. 19 Illinois in Week 4, while SMU has knocked off then-No. 22 Louisville and then-No. 18 Pittsburgh. The winner will meet Boise State in the Fiesta Bowl. 10-seed Indiana (+230) vs. 7-seed Notre Dame (-7.5) The Hoosiers may be the biggest surprise in college football this season, although their inclusion came with a few concerns over the strength of their schedule. After falling flat in a potential statement game against then-No. 2 Ohio State on Nov. 23, Indiana can prove its might against a Fighting Irish squad that won its last 10 games. The winner will take on Georgia in the Sugar Bowl. National Championship Odds and Picks Oregon was the betting favorite (odds via FanDuel) prior to the final rankings reveal at +230. Post-reveal, Texas and Georgia are co-favorites at +360, followed by Oregon at +380, Ohio State at +500 and Penn State at +600. Boise State is the biggest long shot at +7500 despite having a first-round bye. Like Boise State, Arizona State saw its odds go from +3500 to +6000 even though it doesn't play until the quarterfinals. The Picks are In... First-Round Best Bet: Indiana-Notre Dame UNDER 51.5-both teams have solid offenses but will find it difficult to move the ball against the other's defense. Upset Special: Clemson (+340) over Texas-Cade Klubnik will have his hands full against the Texas secondary, but the Clemson defense could be up for the challenge against Quinn Ewers and the Longhorns offense. National Championship Winner: Favorite-Oregon +380; Dark Horse-Notre Dame +1200; Long Shot-Arizona State +6000 --Field Level Media

The stock market is sizzling hot right now. Many exchange-traded funds (ETFs) offered by Vanguard are performing exceptionally well. Nearly half of the Vanguard's 88 ETFs have delivered total returns of at least 20% in 2024. Some of these skyrocketing ETFs aren't surprises. However, one Vanguard ETF you might not think would be a big winner is near its all-time high. And it could soar even more. A surprising highflier It makes sense that funds such as the Vanguard S&P 500 Growth ETF and the Vanguard Mega-Cap Growth ETF are up big. Investors continue to flock to seemingly any stock with the slightest connection with artificial intelligence (AI). They're especially bullish about artificial intelligence (AI) giants including Nvidia , Broadcom , and Oracle . Plenty of other megacap stocks that aren't in the technology space, such as American Express and Walmart , have also chalked up huge gains. However, small-cap stocks have lagged behind large-cap stocks for years. Value investors have also seen the kinds of stocks they prefer trail behind as investors enthused over sexier growth stocks. If you think this hasn't boded well for the Vanguard Small-Cap Value ETF ( VBR -0.04% ) , which owns small-cap value stocks, you're right. As of July 1, the ETF had risen by only 0.33% year to date, while the Vanguard S&P 500 Growth ETF was up 24%. But it's a much different story now. Over the last few months, the Vanguard Small-Cap Value ETF has taken off. The ETF reached a record high in late November and is still close to that level. Most of the 836 stocks in this Vanguard ETF's portfolio aren't anywhere close to being as glamorous as Nvidia and Walmart. Its top holdings include stocks such as Smurfit WestRock and EMCOR Group . You probably won't see much coverage on these stocks. However, many of them are gaining steam. Why this Vanguard ETF could go much higher I think this momentum will continue, pushing the Vanguard Small-Cap Value ETF much higher. This ETF has several tailwinds that are either already blowing, or could do so soon. Arguably the most important one is that the Federal Reserve has lowered interest rates twice over the last three months. Small-cap stocks tend to be especially sensitive to interest rates. Smaller companies often rely more heavily on borrowing than larger companies. Lower rates translate to lower borrowing costs and higher profits. There are also good prospects for deregulation in a second Trump administration. President-elect Trump has promised to eliminate 10 existing regulations for every new regulation added. If he delivers on this pledge, it should be great news for smaller companies. Regulatory costs frequently hit smaller companies harder than larger companies. Trump's proposed steep tariffs on all imports to the U.S. could also benefit many small-cap companies that compete with rivals based outside the U.S. The other factor I expect to work in the Vanguard Small-Cap Value ETF is the tendency for the valuation gap between small-cap and large-cap stocks to revert to the mean. In August 2024, the gap between the valuation of small-cap stocks and large-cap stocks was the greatest since 1998 and 1999. Over the next 11 years, small-cap stocks outperformed large-cap stocks. History is on its side Small-cap stocks have historically delivered higher returns than large-cap stocks by around 10% during the first 12 months after an initial interest rate cut by the Federal Reserve. Since 1936, small-cap stocks have outperformed large-cap stocks, while value stocks have outperformed growth stocks. I think the Vanguard Small-Cap Value ETF is a good pick for investors in the new year. I view it as an even better pick over the long term. History is on this Vanguard ETF's side.BY KEN POWTAK Associated Press BOSTON - Boston College coach Bill O'Brien showed his team the final drive that led up to Heisman Trophy winner Doug Flutie's Hail Mary pass 40 years ago, expressing the need for them to play a complete game. They didn't need any late drama on Saturday after blowing out North Carolina early. Quarterback Grayson James threw for a touchdown and ran for another, and BC celebrated the anniversary of Flutie's pass with a 41-21 victory over North Carolina. "In this room on Friday. I showed them the last drive of the Miami game," O'Brien said. "When you have the '84 team here, they were 10-2, ranked fifth in the country, Heisman Trophy winner in the house, you've got to play well." Ryan Turner added a 78-yard interception return for BC (6-5, 3-4 Atlantic Coast Conference), which became bowl eligible under first-year coach O'Brien. It's the second straight and eighth in the last nine years the Eagles have a bowl opportunity. "You know what he's done, done for this program. Just being able to see guys come back like that and support, it's awesome," James said of Flutie being on the sideline. "It makes us want to put on a show for them." Flutie and many of his 1984 teammates were honored on the field before the second quarter. He hit Gerard Phalen with a 48-yard TD as time expired in BC's Miracle in Miami on Nov. 23, 1984. Making his second straight start after O'Brien benched Thomas Castellanos, James, a transfer from Florida International, completed 18 of 27 passes for 192 yards and no interceptions. Castellanos left the team after he was benched. Tar Heels running back Omarion Hampton, who entered the day second in FBS in rushing at 142.2 yards per game, was held to 53 on 11 carries. Jacolby Criswell completed 16 of 30 passes for 176 yards with three interceptions for North Carolina (6-5, 3-4), which had a three-game winning streak snapped. "I'm really surprised," Tar Heels coach Mack Brown said. "I thought they played hard, they kept trying, they were frustrated some. They were disappointed some, but I did think they tried hard." With BC leading 17-7 after the Tar Heels scored on a 95-yard kickoff return by Chris Culliver, Eagles linebacker Joe Marinaro picked off Criswell and returned it to North Carolina's 32. Three plays later, James hit Reed Harris with an 18-yard fade into the right corner of the end zone with 40 seconds left in the first half, moving BC ahead 24-7. James had a 3-yard TD run, pushing the Eagles ahead 10-0 early in the second quarter. Criswell threw an off-balance pass under pressure that Turner picked off before racing down the left sideline for a score that put it away early in the third. "I came down. I knew someone was behind me trying to get my ankles," Criswell said. "As soon as I came down, tried to throw it out of bounds, I guess all my momentum going down, the ball just floated up and went right to him." The takeaway North Carolina: A week after becoming bowl eligible, the future of Brown could become a hotter topic this week after his team looked overmatched. Boston College: With the addition of James, the offense looks like it fits O'Brien's style much better. He's more of a drop-back passer as opposed to Castellanos, who liked to break out of the pocket often. Up next North Carolina: Hosts North Carolina State next Saturday in its regular-season finale. Boston College: Faces Pittsburgh at home in its final regular-season game Saturday.

Keefe, Bruyette & Woods Begins Coverage on Northeast Bank (NASDAQ:NBN)